Tag: Astrazeneca

Posted on

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown – FierceBiotech


Reuters UK

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown
FierceBiotech
Receptos, meanwhile, in-licensed an IL-13 drug from AbbVie after the pharma company decided to de-prioritize its respiratory efforts, including a program for asthma. Receptos is testing RPC4046 for Eosinophilic esophagitis, an orphan disease, and …
AstraZeneca starts final-stage tests on severe asthma drugReuters
AstraZeneca share price: Drugmaker starts late-stage asthma drug trialiNVEZZ
AZ severe asthma drug tralokinumab goes into Phase IIIPharmaTimes
IFA Magazine
all 15 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca starts final-stage tests on severe asthma drug – Reuters


Reuters UK

AstraZeneca starts final-stage tests on severe asthma drug
Reuters
Several firms are racing to develop injectable biotech asthma drugs for patients with severe disease who do not respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion a year. (Reporting by Ben Hirschler, Editing …
AstraZeneca Starts Phase III Trial For Asthma Drug TralokinumabLondon South East
AstraZeneca Starts Late-stage Study Of Tralokinumab – Quick FactsRTT News

all 4 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca Buys Synairgen Asthma Drug For $7.25M – BioResearch Online (press release)

AstraZeneca Buys Synairgen Asthma Drug For $7.25M
BioResearch Online (press release)
AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. SNG001 is …

and more »

View full post on asthma – Google News

Posted on

AstraZeneca makes small front-end bet on potential asthma drug – Philly.com (blog)


Reuters

AstraZeneca makes small front-end bet on potential asthma drug
Philly.com (blog)
Having fended off Pfizer – for now, at least – AstraZeneca struck a much smaller deal to license a potential asthma drug being developed by Synairgen. AstraZeneca is based in the United Kingdom – London for now, but moving the headquarters to Cambridge …
AstraZeneca builds pipeline with $232 million Synairgen asthma dealReuters
AstraZeneca licenses IFN-beta therapy for viral-induced asthma exacerbationHealio
AstraZeneca extends global shopping spree with $232M asthma drug dealFierceBiotech
BioWorld Online
all 55 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca builds pipeline with $232 million Synairgen asthma deal – Fox Business


Reuters UK

AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Fox Business
AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest drugmaker – subject of a …
AstraZeneca extends global shopping spree with $232M asthma drug dealFierceBiotech
Synairgen breathes easier with $225M from Astrazeneca for its asthma drugBioWorld Online

all 35 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca builds pipeline with $232 million Synairgen asthma deal – Reuters


Reuters

AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Reuters
AstraZeneca plans to start a mid-stage Phase IIa study with the drug in early 2015 in patients with severe asthma, building on results from an initial Phase lla trial in a broad asthma population. Severe asthma is a growing focus for major drugmakers …
Synairgen shares soar on AstraZeneca asthma dealProactive Investors UK
AstraZeneca licenses rights to Synairgen asthma drugThe West Australian

all 16 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca builds pipeline with $232 million Synairgen asthma deal – Yahoo News

AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Yahoo News
LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest …
AstraZeneca Licences Asthma Exacerbation Treatment From SynairgenLondon South East
AstraZeneca licenses rights to Synairgen asthma drugMSN Money
Synairgen shares soar on AstraZeneca asthma dealProactive Investors UK
Cambridge Network
all 7 news articles »

View full post on asthma – Google News